Efficacy of Azithromycin and Miltefosine in Experimental Systemic Pythiosis in Immunosuppressed Mice

We evaluated the efficacy of azithromycin (50 mg/kg, every 12 h [q12h] orally) and miltefosine (25 mg/kg, q24h orally) treatments in an experimental model of vascular/disseminated pythiosis in immunosuppressed mice. Azithromycin was the only treatment able to reduce mortality. The histopathological...

Full description

Saved in:
Bibliographic Details
Published in:Antimicrobial agents and chemotherapy 2019-01, Vol.63 (1)
Main Authors: Loreto, Erico S, Tondolo, Juliana S M, de Jesus, Francielli P K, Verdi, Camila M, Weiblen, Carla, de Azevedo, Maria I, Kommers, Glaucia D, Santurio, Janio M, Zanette, Régis A, Alves, Sydney H
Format: Article
Language:English
Subjects:
Animals
Antiprotozoal Agents
Antiprotozoal Agents - therapeutic use
Azithromycin
Azithromycin - therapeutic use
Experimental Therapeutics
Immunocompromised Host - immunology
Mice
Phosphorylcholine
Phosphorylcholine - analogs & derivatives
Phosphorylcholine - therapeutic use
Pythiosis
Pythiosis - drug therapy
Pythiosis - parasitology
Pythium
Pythium - drug effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We evaluated the efficacy of azithromycin (50 mg/kg, every 12 h [q12h] orally) and miltefosine (25 mg/kg, q24h orally) treatments in an experimental model of vascular/disseminated pythiosis in immunosuppressed mice. Azithromycin was the only treatment able to reduce mortality. The histopathological findings showed acute vascular inflammation, pathogen dissemination, necrotizing myositis, neuritis, and arteritis. The results suggest that azithromycin, but not miltefosine, may have clinical relevance in the treatment of vascular/disseminated pythiosis.
ISSN:0066-4804
1098-6596
DOI:10.1128/AAC.01385-18